VCIM
ELEV

Velan Capital Investment Management’s Elevation Oncology ELEV Stock Holding History

Velan Capital Investment Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-45,000
Closed -$11.7K – 51
2025
Q1 		$11.7K Hold
45,000
– – 0.01% 47
2024
Q4 		$25.3K Buy
+45,000
New +$26.6K 0.02% 43
2024
Q3 		– Sell
-597,299
Closed -$1.61M – 19
2024
Q2 		$1.61M Buy
597,299
+100,000
+20% +$377K 0.92% 13
2024
Q1 		$2.55M Hold
497,299
– – 1.16% 14
2023
Q4 		$267K Hold
497,299
– – 0.16% 20
2023
Q3 		$330K Hold
497,299
– – 0.27% 29
2023
Q2 		$756K Buy
+497,299
New +$1.31M 0.7% 27

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Velan Capital Investment Management's ELEV Position: Q2 2025 in Review

Velan Capital Investment Management sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 45,000 shares — an estimated $11.7K sold.

Velan Capital Investment Management first reported a position in ELEV in Q2 2023 and held it in 7 quarters. The position peaked at $2.55M in Q1 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Velan Capital Investment Management reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Velan Capital Investment Management sold 45,000 Elevation Oncology shares in Q2 2025, an estimated $11.7K.
  • Velan Capital Investment Management first reported a position in Elevation Oncology in Q2 2023 and held it in 7 quarters.
  • Velan Capital Investment Management's Elevation Oncology position peaked at $2.55M in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Velan Capital Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.